Sugi Predict

Sugi Predict / Compounds / Ufiprazole

Ufiprazole

Ufiprazole

SCHEMBL13645428

[2H]c1nc(C([2H])([2H])Sc2nc3cc(OC([2H])([2H])[2H])ccc3[nH]2)c(C([2H])([2H])[2H])c(OC([2H])([2H])[2H])c1C([2H])([2H])[2H]

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BRS3 P32247 2/20 0.42
▸ CYP2E1 P05181 15/20 0.37
▸ CYP2C8 P10632 15/20 0.37
▸ CYP2D6 P10635 15/20 0.37
▸ CYP2C9 P11712 15/20 0.37
▸ CYP2B6 P20813 15/20 0.37
▸ CYP2C19 P33261 15/20 0.37
▸ CYP1A2 P05177 14/20 0.37
▸ CYP3A4 P08684 14/20 0.37
▸ NOS3 P29474 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ufiprazole SCHEMBL13645476 0.98 BRS3 (0.45) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
Ufiprazole SCHEMBL13645534 0.91 BRS3 (0.52) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
Ufiprazole SCHEMBL13645473 0.89 BRS3 (0.56) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
SCHEMBL13645453 0.86 SENP1 (0.37) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
Ufiprazole SCHEMBL13645377 0.85 BRS3 (0.59) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
Ufiprazole SCHEMBL13645485 0.85 BRS3 (0.58) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
Ufiprazole SCHEMBL13645507 0.83 BRS3 (0.62) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
SCHEMBL13657706 0.83 DDAH1 (0.36) BRS3TP53
SCHEMBL13645441 0.82 SENP1 (0.41) BRS3CYP2E1CYP2C8CYP2D6CYP2C9
Omeprazole SCHEMBL13645431 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598273-B2 Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties AUSPEX PHARMACEUTICALS, INC (US) 2009-10-06 — — US disclosed
US-20090215831-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-27 — — US disclosed
US-20090209592-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-20 — — US disclosed
US-20070082929-A1 Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties AUSPEX PHARMACEUTICALS, INC. 2007-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209592-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES ATP4A, ATP6V1G1, ATP6V1E1 BRS3 2346/4885CYP2E1 1399/4885CYP2C8 1100/4885
US-20070082929-A1 Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties ATP4A, ATP6V1G1, ATP6V1E1 BRS3 2346/4885CYP2E1 1399/4885CYP2C8 1100/4885
US-20090215831-A1 INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES ATP4A, ATP6V1G1, ATP6V1E1 BRS3 2346/4885CYP2E1 1399/4885CYP2C8 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.